Global Targeted DNA RNA Sequencing Market Size Likely to Grow at a CAGR of 18.5% By 2035

The market size of the global Targeted DNA RNA Sequencing will be estimated at USD 8.6 billion in 2025 and is expected to grow between USD 10.2 billion in 2026 and about USD 46.9 billion by 2035 with a current CAGR of 18.5% during the period of 2026 to 2035.

Targeted DNA RNA Sequencing Market Revenue and Trends

Targeted DNA and RNA sequencing employs a specialized next-generation sequencing approach which permits researchers to study selected genetic materials and specific genomic areas and recognized RNA molecules which have established clinical or biological value, instead of conducting a complete genomic or transcriptomic study. The method uses established DNA or RNA target selection methods through amplicon-based or hybrid-capture panel technologies to enrich selected genetic materials, which enables researchers to focus their sequencing efforts on the most valuable genomic areas. The method permits scientists to achieve deep sequencing coverage combined with strong detection abilities which allow for precise identification of genetic alterations that include mutations and copy number changes and gene fusions and expression variations, even when working with minimal or substandard samples.

What are the Factors That Have a Significant Contribution to the Growth of the Targeted DNA RNA Sequencing Market?

The targeted DNA and RNA sequencing market grows because government organizations and health agencies require genomic data to monitor infectious diseases and track pathogen evolution and detect initial disease outbreaks. Testing facilities can use targeted sequencing panels to detect specific pathogens and their variants together with antimicrobial resistance indicators which makes these panels suitable for use in routine surveillance operations. National genomics initiatives and better public health systems and knowledge from recent global health emergencies drive the progress of targeted DNA and RNA sequencing for continuous disease monitoring and community health assessment.

Additionally, the targeted DNA and RNA sequencing market continues to grow because pharmaceutical and biotechnology companies use these technologies to discover biomarkers and confirm research targets and develop companion diagnostics. Targeting specific genomic sequences enables researchers to investigate essential medical genes and biological pathways which supports the development of patient classification systems and clinical trial designs and treatment outcome assessments. The approach demonstrates its greatest effectiveness in translational research because scientists can use genomic discoveries for clinical applications while the method delivers results at reduced costs and with high accuracy and reliability.

Segment Insight

By Application

The human biomedical research segment growing at a significant rate over the projected period. The segment exists as the leading segment because academic researchers and clinical researchers now prefer targeted sequencing for their work in cancer genomics and rare disease research and biomarker discovery, combined with the rising funds allocated to precision medicine initiatives and large-scale genomic projects.

Regional Insights

North America held the highest market share in 2025. The revenue growth of the region is supported by three factors, which include the fast adoption of liquid biopsy-targeted sequencing technology and the active research and development work of pharmaceutical companies and biotechnology firms and the comprehensive clinical trial studies which use targeted genomic tests. North America has emerged as a key driver of worldwide market revenue because its leading sequencing technology providers and their growing reimbursement support for clinically validated NGS panels and their beneficial regulatory frameworks continue to drive market growth.

Besides, the Asia Pacific market has the highest rate of growth in the Targeted DNA RNA Sequencing market. The rising cancer rates and growing elderly population together with increased understanding of molecular testing for early cancer detection and specific treatment selection are driving greater demand from hospitals and diagnostic labs. This is expected to drive the regional market.

Report Scope

Recent Developments

• In February 2025, Volta Labs, which operates as a top genomics applications company, revealed its strategic focus areas for 2025 together with its new Callisto App capabilities that now feature RNA library preparation and single-cell preparation and multi-sequencer support. (Source: https://www.prnewswire.com/news-releases/volta-labs-unveils-2025-application-roadmap-for-ngs-sample-prep-at-agbt-302382988.html)

List of the prominent players in the Targeted DNA RNA Sequencing Market:

• Illumina

• F. Hoffman-La Roche Ltd.

• QIAGEN

• Thermo Fisher Scientific Inc.

• Bio-Rad Laboratories Inc.

• Oxford Nanopore Technologies

• PierianDx

• Genomatix GmbH

• DNASTAR Inc.

• Perkin Elmer Inc.

• Others

The Targeted DNA RNA Sequencing Market is segmented as follows:

By Technology

• NGS

  • Method

    • Exome Sequencing

    • Enrichment Sequencing

    • Amplicon Sequencing

    • Others

  • Application

    • Cancer Gene Sequencing

    • Inherited Disease Screening

    • Drug Development

    • Forensic Genomics

    • 16S ribosomal RNA (rRNA) sequencing

• Others

By Workflow

• Data Analysis

• Pre-sequencing

• Sequencing

By Application

• Drug Discovery

• Human Biomedical Research

• Plant & Animal Sciences

• Others

By Type

• DNA Based Targeted Sequencing

• RNA Based Targeted Sequencing

By End Use

• Academic Research

• Pharma & Biotech Entities

• Hospitals & Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America